Launch of previously announced share buy-back programme of up to DKK 1.4 billion

Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

First AML expands Tranche 2 leadership in Australia following major client wins across law and real estate

ASIA’S 50 BEST BARS 2025 REVEALS THE ESTABLISHMENTS RANKED ON THE EXTENDED 51-100 LIST

ASIA’S 50 BEST BARS 2025 REVEALS THE ESTABLISHMENTS RANKED ON THE EXTENDED 51-100 LIST

Blokees Becomes Exclusive Strategic Partner of “Journey of Light: A Glimpse into Ultraman’s 60th Anniversary” Exhibition

Lake Chelan Health enters into Prime Vendor agreement with Medline